In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Gilead Sciences (GILD - Research Report), with a price target of $75.00. The company's shares opened today at $68.07.Syed covers the Healthcare sector, focusing on stocks such as Cytokinetics, Atara Biotherapeutics, and Coherus Biosciences. According to TipRanks, Syed has an average return of -13.1% and a 39.78% success rate on recommended stocks. Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $70.85, implying a 4.08% upside from current levels. In a report released today, RBC Capital also maintained a Buy rating on the stock with a $79.00 price target.
https://www.tipranks.com/news/blurbs/mizuho-securities-reaffirms-their-buy-rating-on-gilead-sciences-gild?utm_source=advfn.com&utm_medium=referral